GlassScriptPhysician profile
Jennifer D Kemmerer
NPI 1700880515
$2,096.44
in general payments reported to CMS, 2019-2025
19 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.72 · 2023: $762 · 2024: $724 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $465.74 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $372.39 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.40 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $227.78 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $140.29 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.39 | 2023-2025 | Xifaxan |
| Novo Nordisk INC | $124.34 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $101.49 | 2024-2025 | Otezla, Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $74.25 | 2023-2024 | Farxiga, Breztri |
| Exact Sciences Corporation | $40.36 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $23.18 | 2024 | Venaseal |
| Antares Pharma, INC. | $22.08 | 2023 | Tlando, Xyosted, Nocdurna |
| Tolmar, INC. | $21.65 | 2024 | |
| Astellas Pharma US INC | $21.44 | 2024 | Veozah |
| Pfizer INC. | $21.26 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.70 | 2023 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $17.56 | 2023 | |
| Esperion Therapeutics, INC. | $16.42 | 2024 | Nexletol |
| Boston Scientific Corporation | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kemmerer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.